About spero therapeutics inc - SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
SPRO At a Glance
Spero Therapeutics, Inc.
675 Massachusetts Avenue
Cambridge, Massachusetts 02139
| Phone | 1-857-242-1600 | Revenue | 59.62M | |
| Industry | Biotechnology | Net Income | 8.57M | |
| Sector | Health Technology | 2025 Sales Growth | 117.619% | |
| Fiscal Year-end | 12 / 2026 | Employees | 25 | |
| View SEC Filings |
SPRO Valuation
| P/E Current | 16.736 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 16.047 |
| Price to Sales Ratio | 2.307 |
| Price to Book Ratio | 2.227 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4,174.641 |
| Enterprise Value to Sales | 1.681 |
| Total Debt to Enterprise Value | 0.029 |
SPRO Efficiency
| Revenue/Employee | 2,384,760.00 |
| Income Per Employee | 342,880.00 |
| Receivables Turnover | 2.348 |
| Total Asset Turnover | 0.664 |
SPRO Liquidity
| Current Ratio | 7.588 |
| Quick Ratio | 7.588 |
| Cash Ratio | 4.54 |
SPRO Profitability
| Gross Margin | N/A |
| Operating Margin | -0.04 |
| Pretax Margin | 14.816 |
| Net Margin | 14.378 |
| Return on Assets | 9.553 |
| Return on Equity | 16.305 |
| Return on Total Capital | 13.845 |
| Return on Invested Capital | 15.781 |
SPRO Capital Structure
| Total Debt to Total Equity | 4.905 |
| Total Debt to Total Capital | 4.676 |
| Total Debt to Total Assets | 4.201 |
| Long-Term Debt to Equity | 1.591 |
| Long-Term Debt to Total Capital | 1.517 |